A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis.
Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM. · 2018
Read A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. by Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6685538.txt.
Introduction
Imperial and co-authors pool patient-level data on treatment-shortening regimens for tuberculosis. Their analysis appears in Nature Medicine. Three pivotal trials tested four-month fluoroquinolone regimens. All three failed their non-inferiority margins. Yet about four-fifths of participants were cured. The team pooled 3,405 participants for answers. External validation checked the findings. High smear grade predicted unfavourable outcomes. HIV positivity and poor adherence did too.
Four-month regimens proved non-inferior in minimal disease. That means low smear grades or no cavitation. A hard-to-treat phenotype emerged at the other end. High smear plus cavitation may need longer therapy. The authors propose stratified treatment duration. One-size-fits-all prescribing could finally end.
Catalog record
| CREATOR | Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis By Marjorie Z. Imperial, Payam Nahid, Patrick P. J. Phillips, Geraint R. Davies, Katherine Fielding, Debra Hanna, David Hermann, Robert S. Wallis, John L. Johnson, Christian Lienhardt, Rada M. Savic Published in: Nature Medicine DOI: 10.1038/s41591-018-0224-2 ABSTRACT Tuberculosis kills more people than any other infectious disease. Three pivotal trials testing 4-month regimens failed to meet non-inferiority margins; however, approximately four-fifths of participants were cured. Through a pooled analysis of patient-level data with external validation, we identify populations eligible for 4-month treatment, define phenotypes that are hard to treat and evaluate the impact of adherence and dosing strategy on outcomes. In 3,405 participants included in analyses, baseline smear grade of 3+ relative to <2+, HIV seropositivity and adherence of ≤90% were significant risk factors for unfavorable outcome. Four-month regimens were non-inferior in participants with minimal disease defined by <2+ sputum smear grade or non-cavitary disease. A hard-to-treat phenotype, defined by high smear grades and cavitation, may require durations >6 months to cure all. Regimen duration can be selected in order to improve outcomes, providing a stratified medicine approach as an alternative to the ‘one-size-fits-all’ treatment currently used worldwide. MAIN Three recent international randomized phase 3 trials evaluating 4-month fluoroquinolone-containing regimens in adults with pulmonary, drug-susceptible tuberculosis failed to achieve non-inferiority compared with the standard 6-month control regimen (OFLOTUB1, ClinicalTrials.gov number NCT00216385; REMoxTB2, ClinicalTrials.gov number NCT00864383; RIFAQUIN3, ISRCTN number 44153044). These trials evaluated later-generation fluoroquinolones (gatifloxacin and moxifloxacin) as single substitutions for ethambutol or isoniazid in multidrug regimens with the objective of shortening treatment duration from 6 to 4 months. In each of the three trials, the 4-month regimen did not satisfy the criteria for non-inferiority. However, the experimental 4-month regimens did cure approximately four-fifths of the participants, suggesting that a large proportion of global tuberculosis cases could be successfully treated with shorter duration1–3. Since the introduction of highly effective rifampin-based regimens in the 1970s and 1980s, the treatment of tuberculosis has been a ‘one-size-fits-all’ paradigm, with a 6-month regimen composed of four drugs (isoniazid, rifampin, pyrazinamide and ethambutol) used for all patients with drug-susceptible pulmonary tuberculosis4,5. Regimen administration is coupled with various adherence interventions at the programmatic level, including directly observed therapy, to ensure regimen intake4. In programs, the one-size-fits-all paradigm leads to undertreatment of patients with severe forms of disease and entails unnecessarily long treatment with potential toxicities for many patients in whom there is a lower disease burden, which in turn may result in increased rates of loss to follow-up6. In clinical trials, one-size-fits-all experimental regimens have been consistently inadequate to cure the hardest-to-treat tuberculosis patients, indicating that treatment duration is a critical determinant for cure7. Moreover, even for the standard 6-month regimen, the recent trials demonstrate that 5–8% of patients fail treatment or relapse and 15–20% experience composite unfavorable outcomes1–3,8. Tuberculosis is not a uniform clinical entity; it presents with wide variation in severity of disease at the time of diagnosis. Yet current tuberculosis regimen development efforts are aimed at using new drugs with increased potency to identify shorter treatments for all patients, regardless of severity of disease. This approach places otherwise efficacious drugs and regimens at risk of being abandoned, consequently impeding the identification of new tuberculosis regimens that would be curative if used with greater precision. In this pooled analysis of individual participant datasets from these high-quality, contemporary trials, we sought to identify characteristics of those participants who were cured with 4-month regimens and, conversely, of those with hard-to-treat phenotypes of tuberculosis, who might require longer treatment durations. We evaluated both baseline characteristics and on-treatment markers of risk, including dosing frequency and adherence, for their ability to stratify the study population into easy- or hard-to-treat phenotypes of tuberculosis. RESULTS Study participants A total of 3,411 study participants treated for drug-susceptible tuberculosis with one of four fluoroquinolone-containing 4-month regimens (n = 2,001) or the standard 6-month regimen (n = 1,404) were included in the modified intent-to-treat analyses of the OFLOTUB1, REMoxTB2, and RIFAQUIN3 trials; 6 participants were excluded from the current analyses due to inability to verify treatment allocation in source databases. The external validation dataset (DMID 01-009; see ref. 9) includes 193 study participants treated with a 4-month experimental regimen (no fluoroquinolone) and 193 study participants treated with the standard 6-month regimen (Fig. 1). Baseline characteristics of participants did not differ across the experimental and control groups within analysis datasets, with the exception of race and enrollment at sites in the country of Senegal (both P < 0.001; Table 1); 12% of the participants were infected with HIV.Fig. 1Analysis and validation populations.Individual participant data from three trials were pooled for analysis. The original results were published in ref. 1 (OFLOTUB), ref. 2 (REMoxTB) and ref. 3 (RIFAQUIN). Data from a fourth trial, DMID 01-009, were used for external validation and previously published in ref. 9. The modified intent-to-treat population was used for the analysis. aFor the validation dataset, the time-to-event analysis population in the original publication was used. bREMoxTB included two 4-month experimental groups.Table 1Baseline characteristics of study participants in the modified intent-to-treat analysisAnalysis dataset (OFLOTUB, REMoxTB, RIFAQUIN)Validation dataset (DMID 01-009)Experimental group (n = 2,001)Control group (n = 1,404)Experimental group (n = 193)Control group (n = 193) Country (no. of participants (%)) Benin122 (6)108 (8)–– Botswana11 (<1)12 (<1)–– China12 (<1)8 (<1)–– Guinea191 (10)184 (13)–– India228 (11)114 (8)–– Kenya165 (8)122 (9)–– Malaysia43 (2)20 (1)––Senegal129 (6)138 (10)––South Africa811 (41)516 (37)––Tanzania122 (6)67 (5)––Thailand65 (3)34 (2)––Zambia35 (2)21 (1)––Zimbabwe67 (3)60 (4)–– Brazil––67 (35)68 (35) Philippines––46 (24)46 (24) Uganda––80 (41)79 (41)Sex (no. of participants (%)) Female592 (30)415 (30)76 (39)76 (39) Race (no. of participants (%)) a Black or African American1,326 (66)1,066 (76)––Asian349 (17)178 (13)––Other326 (16)160 (11)–– Age (years) b Median30292927Interquartile range24–3924–3823–3822–36 Weight (kg) Median52525455Interquartile range46–5847–5849–6249–61BMI (kg m−2)cMedian18.418.320.319.5Interquartile range16.9–20.216.9–20.118.7–22.218.5–22.0 HIV status (no. of participants (%)) d HIV positive248 (12)220 (16)0 (0)0 (0) CD4 + cell count e Median363317––Interquartile range265–493241–444––≤300 (no. of participants)7481–– >300 (no. of participants)13599–– Cavitation (no. of participants (%)) f Cavitation present1,247 (62)847 (60)0 (0)0 (0) Smear (no. of participants (%)) g Negative151 (8)85 (6)85 (44)85 (44)1+332 (17)232 (17)26 (14)30 (15)2+503 (25)404 (29)32 (17)36 (18)3+988 (49)667 (48)50 (26)42 (22)aRace was missing for all OFLOTUB study participants; black race was assigned to all study participants given all OFLOTUB sites were in Africa.bAge was missing for 5 study participants.cBMI was defined as the weight in kilograms divided by the squared height in meters. Height was missing for 291 study participants; median height for females and males were used to calculate BMI for those participants.dHIV status was missing for 9 study participants.eCD4+ cell count cutoff was variable across trials (described in Supplementary Table 2). CD4+ cell count summary statistics were based only on study participants co-infected with HIV but were missing for 79 HIV co-infected study participants.fCavitation status was missing for 200 study participants.gSmear grade was based on clinical trial-defined grading but readjusted so all data were on the same scale. Smear grade was missing for 43 study participants. Primary outcome analysis Multivariate Cox analysis of baseline risk factors for unfavorable outcomes included 3,154 of 3,405 participants (93%) with no missing baseline covariates; 1,843 of 2,001 participants (92%) were allocated to one of the 4-month experimental regimens, and 1,311 of 1,404 participants (93%)